STRATEGY TO MINIMIZE THE BLEEDING RISKS IN PATIENTS WITH ATRIAL FIBRILLATION WHO RECEIVE COMBINED ANTITHROMBOTIC THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION

The use of combined antithrombotic therapy in patients with atrial fibrillation who underwent percutaneous coronary interventions is associated with an increased risk of bleeding. In this regard, minimizing haemorrhagic risk is one of the strategic priorities in the management of this clinical group...

Deskribapen osoa

Xehetasun bibliografikoak

Egile nagusia:	D. A. Zateishchikov
Formatua:	Artigo
Hizkuntza:	Russo
Argitaratua:	«REMEDIUM GROUP» Ltd. 2018-05-01
Saila:	Атеротромбоз
Gaiak:	atrial fibrillation percutaneous coronary intervention combined antithrombotic therapy bleeding risk dabigatran rivaroxaban apixaban
Sarrera elektronikoa:	https://www.aterotromboz.ru/jour/article/view/148
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!